D-0015-2021 Class III Terminated

Recalled by PAI Holdings, LLC. Dba Pharmaceutical Associates Inc — Greenville, SC

FDA drug recall D-0015-2021 was initiated by PAI Holdings, LLC. Dba Pharmaceutical Associates Inc on Sep 9, 2020 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications; high out of specification results obtained at the 9 month stability timepoint The recall status is terminated (terminated Feb 22, 2022). Affected quantity: 13480 cups.

Recall details

Product Type
Drugs
Report Date
Oct 14, 2020
Initiation Date
Sep 9, 2020
Termination Date
Feb 22, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
13480 cups

Product description

Citalopram Oral Solution, USP 20 mg/10 mL, 10 mL unit dose cups, Rx Only, Mfg for: Pharmaceutical Associates, Inc. Greenville, SC 29605 NDC 0121-1696-40

Reason for recall

Failed Impurities/Degradation Specifications; high out of specification results obtained at the 9 month stability timepoint

Distribution pattern

Nationwide.

Code information

Lots: C1EE Exp. 04/2021, BD82 Exp. 11/2020, BD83 Exp. 11/2020, C16D Exp. 02/2021, C563 Exp. 11/2021, C574 Exp. 11/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0015-2021
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0015-2021. Report a data issue: hello@regdatalab.com.